Cannabinoid Research Initiative of Saskatchewan explained

Cannabinoid Research Initiative of Saskatchewan
Type:Affiliated organization of University of Saskatchewan
Location:Saskatoon, Saskatchewan, Canada
Services:Academic and applied research Cannabinoids
Medical Marijuana
Cannabis
Cannabidiol

The Cannabinoid Research Initiative of Saskatchewan (CRIS) was founded in 2017 as an interdisciplinary research team of clinician researchers (medical and veterinary), basic scientists, and social scientists. CRIS aims to obtain scientific evidence about the application of Cannabinoids and Medical cannabis to humans and animals, for health, disease and disorders. The team was initially based at the University of Saskatchewan, in Saskatoon, Saskatchewan, Canada but includes researchers based at the University of Regina and University of Alberta. A strategic management executive committee coordinates activities and develops research opportunities. The sections of CRIS include: Analytical Evaluations, Human Clinical Studies, Biomedical studies, Veterinary Sciences, Knowledge Translation and Studies of Cannabinoids and Society. CRIS members participate in the Canadian Consortium for the Investigation of Cannabinoids,[1] and the International Cannabinoid Research Society.[2]

The CARE-E clinical trial of a cannabis oil with high cannabidiol content with pediatric patients with refractory epilepsy was a key factor in initiating the research initiative. The CARE-E trial is a multi-center phase one trial that currently has open enrollment in five Canadian cities.[3] The CARE-E trial received extensive media coverage when it was launched.[4] [5] The therapeutic effect of pure cannabidiol (Epidiolex GW Pharmaceuticals) on Dravet Syndrome was recently reported in the New England Journal of Medicine[6] [7]

The CRIS group has expanded to biomedical science studies of the pharmacology of cannabinoids and synthetic cannabinoids.[8]

Laboratories

(i) Determinants of neonatal exposure risk when breastfeeding mothers require medications.

(ii) Research into the health benefits of flaxseed lignans and their underlying mechanism(s) of action.[9] [10]

(i) Clinical trials looking at cannabis in pediatric neurological disease.

(ii) Neuro-degenerative and neuro-metabolic disorders of childhood[12]

External links

See also

Notes and References

  1. Web site: The Canadian Consortium for the Investigation of Cannabinoids . ccic.net. 2017-12-27.
  2. Web site: The International Cannabinoid Research Society . icrs.co. 2017-12-27.
  3. Web site: Cannabidiol in Children With Refractory Epileptic Encephalopathy - Full Text View – NCT03024827. ClinicalTrials.gov. 2017-12-27.
  4. Web site: Researchers studying usage, safety of cannabis oil for children with epilepsy - Saskatchewan - CBC News. cbc.ca. 2017-12-27.
  5. Web site: U of S study looks at using cannabis oil to treat children with epilepsy - Saskatoon. Globalnews.ca. 2017-12-27.
  6. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome - NEJM . The New England Journal of Medicine. 376. 21. 2011–2020. 10.1056/NEJMoa1611618. 28538134. 2017. Devinsky. O.. Cross. J. H.. Laux. L.. Marsh. E.. Miller. I.. Nabbout. R.. Scheffer. I. E.. Thiele. E. A.. Wright. S.. Cannabidiol in Dravet Syndrome Study Group. 20.500.11820/2ed5e0db-7de9-4411-93d7-3a5c388006b9. 86481485 . free.
  7. Cannabinoids for Epilepsy — Real Data, at Last - NEJM. The New England Journal of Medicine. 376. 21. 2075–2076. 10.1056/NEJMe1702205. 28538129. 2017. Berkovic. S. F..
  8. Bidirectional allosteric interactions between cannabinoid receptor 1 (CB1) and dopamine receptor 2 long (D2L) heterotetramers.. 28734930 . 10.1016/j.ejphar.2017.07.034 . 813. 2017. Eur J Pharmacol. 66–83 . Bagher . AM . Laprairie . RB . Toguri . JT . Kelly . MEM . Denovan-Wright . EM. 25878852 .
  9. Web site: Discovery Research Group. usask.ca. 2017-12-27.
  10. Web site: Jane Alcorn - College of Pharmacy and Nutrition - University of Saskatchewan. pharmacy-nutrition.usask.ca. 2017-12-27.
  11. Web site: Charity Evans - College of Pharmacy and Nutrition - University of Saskatchewan. pharmacy-nutrition.usask.ca. 2017-12-27.
  12. Web site: Richard Huntsman - College of Medicine - University of Saskatchewan. medicine.usask.ca. 2017-12-27.
  13. Web site: Robert Laprairie - College of Pharmacy and Nutrition - University of Saskatchewan. pharmacy-nutrition.usask.ca. 2017-12-27.
  14. Web site: Lab Website for Dr. Matthew Links . coadunate.net. 2017-12-27.
  15. Web site: Holly Mansell - College of Pharmacy and Nutrition - University of Saskatchewan. pharmacy-nutrition.usask.ca. 2017-12-27.
  16. Web site: Kerry Mansell - College of Pharmacy and Nutrition - University of Saskatchewan. pharmacy-nutrition.usask.ca. 2017-12-27.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cannabinoid Research Initiative of Saskatchewan".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.